Jemperli Gets FDA Approval To Take Its Place In Cancer Therapy
GlaxoSmithKline’s immunotherapy drug, Jemperli (dostarlimab-gxly), is making significant strides in oncology, particularly in treating endometrial…
Articles
Kineret (Anakinra) For The Treatment Of COVID-19-Associated Pneumonia Expands Its Immunomodulatory Applications
The U.S. Food and Drug Administration (FDA) has expanded its approval of Sobi’s (Swedish Orphan…
Oral Lupus Nephritis Drug Lupkynis (Voclosporin) Changing The Treatment Landscape
April 17, 2025 — Lupus nephritis (LN) is a serious autoimmune disease that has long…
Braftovi Combo Shows Promising Survival Benefits In BRAF-Mutant Colorectal Cancer
In a significant advancement for metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations, Pfizer’s…
Ensartinib Shows Strong Efficacy in ALK-Positive Non-Small Cell Lung Cancer
Highlighted by Hong Kong DengYue Medicine What is Ensacove Ensartinib? Ensacove Ensartinib (X-396) is an…
Phase 3 Trial Of Crenessity (Crinecerfont) In Pediatric Congenital Adrenal Hyperplasia
The U.S. Food and Drug Administration (FDA) has approved Crenessity™ (crinecerfont) as an adjunctive treatment…
FDA Approves Alhemo: A Breakthrough In Hemophilia Treatment
In a significant advancement for hemophilia care, the U.S. Food and Drug Administration (FDA) has…
Beovu For Diabetic Macular Edema: A New Era In Retinal Disease Treatment
In a significant advancement for retinal disease management, the U.S. Food and Drug Administration (FDA)…
Ionis Launches Tryngolza™ (Olezarsen) for FCS With Positive Phase 3 Data and $595,000 Annual List Price
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the official U.S. launch of Tryngolza™ (olezarsen), a…
Cablivi’s 2025 Outlook: Advancements And Challenges In Treating ATTP
In 2025, Sanofi’s Cablivi (caplacizumab-yhdp) continues to play a pivotal role in the management of…